Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Breast 1

Conditions

Triple Negative Breast Neoplasms 23Breast Neoplasms 18Neoplasm Metastasis 2Her-2 Negative Breast Cancer 1HER2-negative Breast Cancer 1Gastrointestinal Neoplasms 1BRCA-Mutated Breast Carcinoma 1Advanced Triple Negative Breast Cancer 1

Interventions

Surveys and Questionnaires 7Nivolumab 5atezolizumab 3Radiosurgery 3Blood Specimen Collection 3pertuzumab 2pembrolizumab 2pazopanib 2cemiplimab 2amminedichloro(2-methylpyridine)platinum(II) 2alectinib 2Magnetic Resonance Spectroscopy 2Interviews as Topic 2Drug Therapy 2Capecitabine 2tepotinib 1talazoparib 1selpercatinib 1pralsetinib 1ponatinib 1pemigatinib 1palbociclib 1motexafin gadolinium 1montanide ISA 51 1mannide monooleate 1itacitinib 1ipatasertib 1fludarabine 1entrectinib 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gastrointestinal Neoplasms × camrelizumab × Breast × Clear all
NCT02742935 2023-02-27

A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Completed
99 enrolled
BreastGastrointestinal

Breast Neoplasms, Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡